Cardiovascular disease is the leading cause of death worldwide, with this trend predicted to
continue for the foreseeable future. Common disorders are associated with the stenosis or …

Cardiovascular diseases (CVDs) account for the 31% of total death per year, making them
the first cause of death in the world. Atherosclerosis is at the root of the most life-threatening …

In the active field of vascular graft research, polycaprolactone is often used because of its
good mechanical strength and its biocompatibility. It is easily processed into micro and nano …

There is a lack in clinically-suitable vascular grafts. Biotubes, prepared using in vivo tissue
engineering, show potential for vascular regeneration. However, their mechanical strength is …

Translation of acute ischemic stroke research to the clinical setting remains limited over the
last few decades with only one drug, recombinant tissue-type plasminogen activator …

There is a persistent and growing clinical need for readily-available substitutes for heart
valves and small-diameter blood vessels. In situ tissue engineering is emerging as a …

Due to poor vessel quality in patients with cardiovascular diseases, there has been an
increased demand for small-diameter tissue-engineered blood vessels that can be used as …

The performance of clinical synthetic small diameter vascular grafts remains disappointing
due to the fast occlusion caused by thrombosis and intimal hyperplasia formation. Poly (vinyl …

Despite much effort, synthetic small diameter vascular grafts still face limited success due to
vascular wall thickening known as intimal hyperplasia (IH). Compliance mismatch between …

Despite the wide variety of tissue‐engineered vascular grafts that are currently being
developed, autologous vessels, such as the saphenous vein, are still the gold standard …